Delcath Systems Shares Up 69% Premarket; Company Announced Late Monday FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
Portfolio Pulse from Charles Gross
Delcath Systems announced that the FDA has approved its HEPZATO KIT for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma. Following the announcement, the company's shares surged by 69% in premarket trading.
August 15, 2023 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Delcath Systems' stock price surged following the FDA approval of its HEPZATO KIT. This approval could potentially increase the company's revenues and market share in the future.
The FDA approval of Delcath Systems' HEPZATO KIT is a significant milestone for the company. This could potentially lead to increased sales and revenues, positively impacting the company's stock price. The 69% surge in premarket trading indicates the market's positive reaction to this news.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100